T0070907

Cat. No. M3044

All AbMole products are for research use only, cannot be used for human consumption.

Size	Price	Availability
1mg	USD 16	In stock
5mg	USD 35	In stock
10mg	USD 50	In stock
50mg	USD 160	In stock
100mg	USD 200	In stock

Free Delivery on orders over USD 500 Bulk Inquiry?

T0070907 is a potent and selective PPARγ inhibitor with IC50 of 1 nM, with a >800-fold selectivity over PPARα and PPARδ.

PLoS Pathog. 2026 Jan;22:e1013786.

Fecal microbiota transplantation ameliorates radiation-induced lung injury by reshaping gut metabolic homeostasis to activate FAM134B-mediated ER-phagy
T0070907 purchased from AbMole
Gut Microbes. 2024 Apr 17;16(1):2334967.

Sialic acid-based probiotic intervention in lactating mothers improves the neonatal gut microbiota and immune responses by regulating sialylated milk oligosaccharide synthesis via the gut-breast axis
T0070907 purchased from AbMole
Biomed Pharmacother. 2024 May 23;176:116760.

Identification of a novel hypoglycemic small molecule, trans-2, 4-dimethoxystilbene by rectifying gut microbiota and activating hepatic AMPKα-PPARγ pathway through gut-liver axis
T0070907 purchased from AbMole

	Source	Environ Health Perspect (2018). Figure 3. T0070907
	Method	Adipogenic Differentiation
	Cell Lines	human and mouse MSCs
	Concentrations	100nM
	Incubation Time	8h
	Results	In hMSCs, T0070907 (100nM) significantly blocked the ability of DBT to induce the accumulation of lipids

Cell Experiment
Cell lines	Vascular endothelial cells (VECs)
Preparation method	Cellular impedance assay VEC proliferation was assessed using a cellular impedance assay. VECs were seeded into 8-well E-plates at a density of 7,500 cells/well and cultured overnight. Cells were cultured with complete medium, supplemented with 0.1% dimethyl sulfoxide (DMSO) as a control, the PPARγ agonist rosiglitazone (10 µM) or the PPARγ antagonist T0070907 (15 µM) respectively, as previously described. Cellular proliferation was dynamically monitored using the iCELLigence real-time cell analysis (RTCA) system at 37°C in a 5% CO2 atmosphere for 100 h. The cell index, which reflects the adhesion, proliferation and viability of the cells through electrical impedance across interdigitated microelectrodes integrated on the bottom of the E-plates, was automatically calculated for each E-plate well using RTCA software version 1.2 and graphs were generated in real-time using the iCELLigence system. Each treatment was performed in duplicate and three independent experiments were conducted.
Concentrations	15 µM
Incubation time	24 h

Animal Experiment
Animal models	Preconditioning is performed by administering a low dose (1 mg/kg) of Escherichia coli LPS (serotype 0.127:B8) intraperitoneally 24 hr before the induction of severe endotoxemia
Formulation	10% v/v dimethylsulfoxide [DMSO], 20–25% v/v DMSO, or saline
Dosages	1 mg/kg
Administration	intraperitoneally

Molecular Weight	277.66
Formula	C12H8ClN3O3
CAS Number	313516-66-4
Solubility (25°C)	DMSO 30 mg/mL
Storage	Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month

Related PPAR Products
WY 14643 (Pirinixic Acid) WY 14643 (Pirinixic Acid) is a potent and selective, peroxisome proliferator-activated receptor-α (PPARα) agonist.
Rosiglitazone Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC50=60 nM, Kd=40 nM). Rosiglitazone is an TRPC5 activator (EC50=30 μM) and TRPM3 inhibitor.
GSK 3787 GSK3787 is an orally available selective peroxisome proliferator-activated receptor δ (PPARδ) antagonist (pIC50 = 6.6).
Rosiglitazone maleate Rosiglitazone maleate (Avandia) is a potent and selective PPARγ ligand that binds to the PPARγ ligand-binding domain with a Kd value of 43 nM.
Ciprofibrate Ciprofibrate is a peroxisome proliferator-activated receptor α (PPARα) agonist.

Catalog